{"denoms":[{"counts":[{"groupId":"BG000","value":"194"},{"groupId":"BG001","value":"97"},{"groupId":"BG002","value":"291"}],"units":"Participants"}],"groups":[{"description":"Cycles 1-8: Venetoclax 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 4, 8 \\& 11 and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 \\& 12; Cycles 9 and beyond: Venetoclax 800 mg orally every day (QD) on Days 1 - 35 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 8, 15 and 22 and dexamethasone 20 mg orally on Days 1, 2, 8, 9, 15, 16, 22 and 23","id":"BG000","title":"Venetoclax + Bortezomib and Dexamethasone"},{"description":"Cycles 1-8: Placebo (to match venetoclax 100 mg tablet) 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 4, 8 \\& 11 and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 \\& 12; Cycles 9 and beyond: Placebo (to match venetoclax 100 mg tablet) 800 mg orally every day (QD) on Days 1 - 35 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 8, 15 and 22 and dexamethasone 20 mg orally on Days 1, 2, 8, 9, 15, 16, 22 \\& 23","id":"BG001","title":"Placebo + Bortezomib and Dexamethasone"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.41","value":"65.9"},{"groupId":"BG001","spread":"7.81","value":"65.9"},{"groupId":"BG002","spread":"8.90","value":"65.9"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"97"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"139"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"97"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"152"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"32"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"169"},{"groupId":"BG001","value":"90"},{"groupId":"BG002","value":"259"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"59"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"87"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"12"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"124"},{"groupId":"BG001","value":"66"},{"groupId":"BG002","value":"190"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"62.0","upperLimit":"8356.0","value":"1263.5"},{"groupId":"BG001","lowerLimit":"195.0","upperLimit":"4906.0","value":"1461.0"},{"groupId":"BG002","lowerLimit":"62.0","upperLimit":"8356.0","value":"1318.0"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Time since diagnosis","unitOfMeasure":"days"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"1.0","upperLimit":"3.0","value":"1.0"},{"groupId":"BG001","lowerLimit":"1.0","upperLimit":"3.0","value":"2.0"},{"groupId":"BG002","lowerLimit":"1.0","upperLimit":"3.0","value":"1.0"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Number of prior lines of therapy","unitOfMeasure":"number of prior lines of therapy"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"91"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"135"}]}],"title":"1 line"},{"categories":[{"measurements":[{"groupId":"BG000","value":"103"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"156"}]}],"title":"2-3 lines"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Number of prior lines of multiple myeloma therapy","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]}],"title":"Refractory"},{"categories":[{"measurements":[{"groupId":"BG000","value":"131"},{"groupId":"BG001","value":"66"},{"groupId":"BG002","value":"197"}]}],"title":"Sensitive"},{"categories":[{"measurements":[{"groupId":"BG000","value":"61"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"89"}]}],"title":"Naïve"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]}],"title":"Unknown"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}],"title":"MISSING"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Prior exposure to proteasome inhibitors (PI)","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"100"}]}],"title":"Refractory"},{"categories":[{"measurements":[{"groupId":"BG000","value":"67"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"96"}]}],"title":"Sensitive"},{"categories":[{"measurements":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"93"}]}],"title":"Naïve"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}],"title":"Unknown"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}],"title":"MISSING"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Prior exposure to an immunomodulatory drug (IMID)","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"6"}]}],"title":"Refractory"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}],"title":"Sensitive"},{"categories":[{"measurements":[{"groupId":"BG000","value":"185"},{"groupId":"BG001","value":"95"},{"groupId":"BG002","value":"280"}]}],"title":"Naïve"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}],"title":"Unknown"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"5"}]}],"title":"MISSING"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Prior exposure to an anti-CD38 monoclonal antibody","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"81"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"129"}]}],"title":"Stage I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"69"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"101"}]}],"title":"Stage II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"52"}]}],"title":"Stage III"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"8"}]}],"title":"Not evaluable"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}],"title":"MISSING"}],"description":"The International Staging System for multiple myeloma:\n\nStage I: Serum β2 microglobulin (Sβ2M), \\< 3.5 mg/L; serum albumin ≥ 3.5 g/dL\n\nStage II: Not ISS Stage I or III\n\nStage III: Sβ2M \\> 5.5 mg/L\n\nStage I represents the mildest form of multiple myeloma (best prognosis) and Stage III the most severe form (worst prognosis).","paramType":"COUNT_OF_PARTICIPANTS","title":"Multiple myeloma International Staging System(ISS) stage","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"49"}]}],"title":"High"},{"categories":[{"measurements":[{"groupId":"BG000","value":"141"},{"groupId":"BG001","value":"72"},{"groupId":"BG002","value":"213"}]}],"title":"Standard"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"13"}]}],"title":"Unknown"},{"categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"16"}]}],"title":"MISSING"}],"description":"A 4 mL bone marrow aspirate sample was collected for baseline assessment of chromosomal abnormalities, including t(11;14), t(4;14), t(14;16), del 17p, 5+, 9+, 15+","paramType":"COUNT_OF_PARTICIPANTS","title":"Chromosomal abnormality (CA) risk by fluorescent in situ hybridization (FISH)","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"114"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"171"}]}],"title":"Autologous"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]}],"title":"Allogeneic"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}],"title":"Syngeneic"},{"categories":[{"measurements":[{"groupId":"BG000","value":"78"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"118"}]}],"title":"MISSING"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Prior stem cell transplant","unitOfMeasure":"Participants"}],"populationDescription":"Intent-To-Treat (ITT) analysis set: all randomized participants, analyzed by treatment group assignment given at the time of randomization"}